ValueScreener
Named tests met3 of 30
185.48 USD Market data. Sources for Share priceClose of Nov 11, 2026

Market data as of Nov 11, 2026. Ratios computed Nov 11, 2026.

ValueScreener company report

NYSE / Healthcare / Drug Manufacturers - General

Reading

The evidence behind it

Overview

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on invested capital, after tax

15.2% Computed

From the FY2025 filing

Read quality

Valuation

Price to earnings

28.13x Computed

FY2025 accounts, priced at 21:00 UTC

Read valuation

Cash generation

Free cash flow yield

4.1% Computed

FY2025 accounts, priced at 21:00 UTC

Read cash generation

Strength

Debt to equity

0.65 Computed

From the FY2025 filing

Read strength

Revenue and net income, as filed

FY2016 Revenue: 23.00B USDFY2016 Net income: 3.50B USDFY2017 Revenue: 22.46B USDFY2017 Net income: 3.00B USDFY2018 Revenue: 22.09B USDFY2018 Net income: 2.15B USDFY2019 Revenue: 24.38B USDFY2019 Net income: 1.33B USDFY2020 Revenue: 26.62B USDFY2020 Net income: 3.20B USDFY2021 Revenue: 37.42B USDFY2021 Net income: 112.0M USDFY2022 Revenue: 44.35B USDFY2022 Net income: 3.29B USDFY2023 Revenue: 45.81B USDFY2023 Net income: 5.96B USDFY2024 Revenue: 54.07B USDFY2024 Net income: 7.04B USDFY2025 Revenue: 58.74B USDFY2025 Net income: 10.22B USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Market capitalisation
287.70B USD Market data. Sources for Market capitalisation21:00 UTC
Filed accounts
FY2025, filed Feb 24, 2026
Filed years
10, FY2016 to FY2025
The business, and the score behind its five axes

The reading, in brief

Is it cheap

Price to earnings is 28.13x at the close of 2026-11-11 on FY2025 figures; the lines are 15.00x (Graham's defensive ceiling) and, by market convention, 10.00x, 25.00x and 40.00x, and this sits between 25.00x and 40.00x.

Today, against the Healthcare sector (224 companies), 28.13x sits at the 50th percentile; the middle half of that group runs from 13.46x to 42.79x.

Is it good

Return on invested capital was 15.2% in FY2025, in the band labelled "Above the cost of capital" (12.0% to 20.0%), on lines anchored on Damodaran's cost-of-capital data.

Today, against the Healthcare sector (236 companies), 15.2% sits at the 79th percentile; the middle half of that group runs from -35.7% to 13.6%.

Is it safe

Interest coverage was 8.11x in FY2025, in the band labelled "Comfortable" (6.00x and above), on lines anchored on Damodaran's interest-coverage table, suggesting an interest bill operating profit covers many times over.

Year by year against peers
Whether AstraZeneca PLC's return on invested capital stayed above the median of the Healthcare sector, year by year. (FY2023 to FY2025, 3 fiscal years of AstraZeneca PLC with a comparable figure)
The direction
Which way AstraZeneca PLC's return on equity has moved, and how steadily. (FY2016 to FY2025, 10 filed years of AstraZeneca PLC)
What could explain it
What in AstraZeneca PLC's filed statements could explain the movements. (7 readings drawn from the statement lines AstraZeneca PLC filed)
What to check next
What to check next on AstraZeneca PLC, and where in its filings. (5 questions for AstraZeneca PLC)
In one paragraph
One paragraph on AstraZeneca PLC's returns, cash, balance sheet and price. (14 of sixteen figures read for AstraZeneca PLC)

These are AZN’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research AZNPart of Serious. New accounts start with 30 days of Professional, free, no card.

What changed

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 20-F, filed Feb 24, 2026, accession 0001104659-26-019130.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

What this cannot tell you

  • 7 figures could not be read on this company, among them Positive Earnings Streak, Eps Growth 5Y, EV/EBITDA. Each blank in the table above names the rest, with its reason. 3 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Then we check your line against newly filed data and write to you the night our data shows it broke. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published. It is Professional, the plan a new account starts on for 30 days, one trial per person.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, and what it can mean for a thesis.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy